SCHEDULE 13D: Velan Capital Takes Significant Stake in Edesa Biotech, Secures Board Representation and Governance Influence

Velan Capital and its affiliated entities have acquired a 9.99% beneficial ownership stake in Edesa Biotech, Inc. through a private placement, gaining a board seat and observer rights, citing the company's shares as undervalued.

Summary

• Velan Capital and its affiliated entities (Velan Master, Velan Horizon, Velan Opportunity II, and related management entities and individuals) have collectively acquired 693,551 Common Shares of Edesa Biotech, Inc., representing 9.99% of the outstanding shares as of February 14, 2025.
• The acquisition was made through a private placement on February 12, 2025, where Edesa Biotech issued and sold 568 Series B-1 Convertible Preferred Shares (stated value $10,000 per share) and 687,500 Common Shares.
• The purchase price was $10,000 per Preferred Share and $1.92 per Common Share, with Preferred Shares convertible into Common Shares at a fixed conversion price of $1.92.
• The Lead Investors (Velan Master, Velan Horizon, Velan Opportunity II) purchased 421,875 Common Shares and 366 Preferred Shares for $4,470,000 (Velan Master), 15,625 Common Shares and 7 Preferred Shares for $100,000 (Velan Horizon), and 250,000 Common Shares and 195 Preferred Shares for $2,430,000 (Velan Opportunity II).
• As part of an Investor Rights Agreement (IRA), Velan Capital secured the right to nominate one individual to Edesa Biotech's Board of Directors, leading to the appointment of David Liu on February 12, 2025.
• David Liu will serve on the Compensation Committee and any strategic review committee formed by the Board.
• Velan Capital is also entitled to designate a non-voting observer to the Board, with Adam Morgan initially filling this role.
• The Board size is set to be reduced to no more than seven members, including the Lead Investor Nominee, after the next annual general meeting of shareholders.
• The Lead Investors' conversion rights for Preferred Shares are subject to an ownership limitation, preventing them from beneficially owning more than 9.99% of outstanding shares immediately after conversion, though this can be increased to 19.99% with 61 days' notice.
• Velan Master also holds 63,492 Warrants to purchase shares at an exercise price of $10.50 per share, expiring on December 23, 2025, also subject to a 9.99% beneficial ownership blocker.

Sentiment

Score: 8

Explanation: The sentiment is highly positive from the investor's perspective, as they explicitly state the securities were 'undervalued and represented an attractive investment opportunity.' Their significant investment, coupled with securing a board seat and protective governance provisions, indicates strong confidence and an intent to drive value. This action is generally viewed positively by the market as it signals an activist investor's belief in the company's potential.

Positives

• Velan Capital believes Edesa Biotech's securities were undervalued, indicating a potential for future appreciation.
• The investment firm has secured a significant beneficial ownership stake of 9.99%, demonstrating strong conviction.
• Gaining a seat on the Board of Directors (David Liu) and an observer role (Adam Morgan) provides Velan Capital direct influence over the company's strategic direction and corporate governance.
• The Lead Investor Nominee will serve on the Compensation Committee and any strategic review committee, allowing for direct input on key operational and strategic decisions.
• Protective provisions in the IRA restrict Edesa Biotech from making adverse changes to its governing documents or Preferred Share rights without Lead Investors' consent, safeguarding their investment.

Negatives

• The ownership limitation restricts the Lead Investors from immediately converting Preferred Shares if it would result in beneficial ownership exceeding 9.99% (or 19.99% with notice), potentially limiting their immediate voting power or liquidity.
• The protective provisions, while beneficial to the Lead Investors, could potentially limit the company's flexibility in future corporate actions or capital structure adjustments without their consent, which might not always align with all shareholders' interests.
• The reduction of the Board size to no more than seven members after the next annual general meeting could lead to fewer independent voices or a more concentrated decision-making body.

Risks

• The Reporting Persons' future investment decisions (increasing or decreasing their position) are dependent on overall market conditions and other investment opportunities, which could lead to volatility in Edesa Biotech's stock.
• The beneficial ownership limitation on the conversion of Preferred Shares and Warrants means that the full potential ownership (37.2% if not for the limitation) is not immediately realized, which could impact the perceived influence of the activist investor.
• The effectiveness of the Lead Investors' strategic influence and the potential for value creation are subject to the cooperation of the existing management and board, and the successful execution of any proposed changes.

Future Outlook

The Reporting Persons may endeavor to increase or decrease their position in Edesa Biotech depending on overall market conditions, other investment opportunities, and the availability of securities at desirable prices. The Issuer has agreed to use its reasonable best efforts to solicit shareholder approval for the Lead Investor Nominee at future shareholder meetings where directors are elected. The Board size is also set to be reduced to no more than seven members after the next annual general meeting.

Management Comments

• The Reporting Persons purchased the securities of the Issuer based on their belief that the securities, when purchased, were undervalued and represented an attractive investment opportunity.

Industry Context

This filing indicates an activist investment in a biotech company, a common strategy where investors take significant stakes to influence corporate strategy, governance, and potentially unlock shareholder value. Such moves often signal a belief in the underlying assets or pipeline of the biotech firm, but also suggest a perceived need for operational or strategic changes to realize that value. This could put pressure on Edesa Biotech's management to improve performance or consider strategic alternatives.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: The significant investment and board representation by Velan Capital could be seen as a positive signal, potentially leading to increased share price if the activist strategy is successful in unlocking value. However, the protective provisions and ownership limitations could also affect future capital raises or corporate actions.
• **Management**: The appointment of a new director and observer from an activist investor group will likely increase scrutiny on management decisions and performance, potentially leading to strategic shifts or operational changes.
• **Employees**: While not directly addressed, strategic changes driven by the new board representation could indirectly impact employees through shifts in company focus, resource allocation, or operational efficiency initiatives.

Next Steps

• The Issuer will use reasonable best efforts to solicit shareholder approval of the Lead Investor Nominee at each general or special meeting of shareholders where directors are elected.
• The size of the Board shall be reduced to no more than seven members, including the Lead Investor Nominee, upon the conclusion of the Issuer's next annual general meeting of shareholders.
• The Reporting Persons may increase or decrease their position in the Issuer based on market conditions and investment opportunities.

Key Dates

Recommendation

Keywords

Edesa Biotech, Velan Capital, Schedule 13D, Private Placement, Convertible Preferred Shares, Board of Directors, Corporate Governance, Activist Investor, Shareholder Rights, Biotech Investment, SEC Filing, Investment Management